The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | The promise of CD123-directed immunotherapy in AML and agents of interest
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promise of CD123-directed immunotherapy in acute myeloid leukemia (AML) and highlights agents being investigated, including vibecotamab, flotetuzumab and pivekimab sunirine. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant for: Celgene/BMS, Astellas, Abbvie, Novartis, Syros, Taiho/Astex, Kite Pharma, Grant/Research support from: Amgen, Xencor, Astex/Taiho, Abbvie, Syros, Prelude, Honoraria from: Celgene/BMS, Astellas, Abbvie, Novartis, Syros, Taiho/Astex, Kite Pharma
